NCT02957123View on ClinicalTrials.gov

Intranasal Inhalations of Bioactive Factors Produced by M2 Macrophages in Patients With Organic Brain Syndrome

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

September 30, 2020

Study Completion Date

September 30, 2020

Conditions
Organic Brain Syndrome, NonpsychoticNeurocognitive DisordersMental Disorder, OrganicDelirium, Dementia, Amnestic, Cognitive DisordersNonpsychotic Organic Brain SyndromeOrganic Mental DisorderEncephalopathy, Post-Traumatic, ChronicEncephalopathy, IschemicBrain Ischemia
Interventions
DRUG

Intranasal auto-M2-BFs

Delivery is performed with the aerosol inhaler device (nebulizer), 2.0 mL once a day up to 30 days.

Trial Locations (1)

630099

Institute of Fundamental and Clinical Immunology, Novosibirsk

All Listed Sponsors
lead

Russian Academy of Medical Sciences

OTHER

NCT02957123 - Intranasal Inhalations of Bioactive Factors Produced by M2 Macrophages in Patients With Organic Brain Syndrome | Biotech Hunter | Biotech Hunter